In conclusion, in the absence of specific contraindications or limited life expectancy, DAA treatment should be promptly offered to oncologic patients with chronic hepatitis C in order to achieve ALT normalization and viremia control, making antineoplastic therapy feasible and safe. This evidence concerns the gene GPT and chronic hepatitis C virus infection.